See today's BioWorldSee today's BioWorld Asia
To read the full story, subscribe or sign in.

Mabwell joins ADC breast cancer race as China clears phase II

July 16, 2024
By Marian (YoonJee) Chu
Mabwell Bioscience Co. gained clearance in China to start a phase II study of its novel Nectin4-targeting antibody drug conjugate (ADC), 9MW-2821, for metastatic triple-negative breast cancer.
BioWorld BioWorld Asia Regulatory Cancer Antibody-drug conjugate Asia-Pacific China U.S. Fast track FDA NMPA